Drug Profile

RV 6153

Alternative Names: RV6153

Latest Information Update: 28 Aug 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator RespiVert
Class Antiasthmatics; Small molecules
Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Phosphotransferase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2019 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
28 Aug 2018 No recent reports of development identified for phase-I development in Asthma in United Kingdom (Inhalation)
03 Mar 2016 Respivert terminates a phase I trial for Asthma in United Kingdom (NCT02517359)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com